Efficacy and safety of high‐dose pravastatin in hypercholesterolemic patients with well‐compensated chronic liver disease: Results of a prospective, randomized, double‐blind, placebo‐controlled, multicenter trial

James H. Lewis, Mary Ellen Mortensen, Steven Zweig, Mary Jean Fusco, Jeffrey R. Medoff, Rene Belder, Pravastatin in Chronic Liver Disease Study Investigators – 29 October 2007 – The hepatotoxic potential of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors in patients with underlying chronic liver disease remains controversial.

N‐glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus

Xue‐En Liu, Liesbeth Desmyter, Chun‐Fang Gao, Wouter Laroy, Sylviane Dewaele, Valerie Vanhooren, Ling Wang, Hui Zhuang, Nico Callewaert, Claude Libert, Roland Contreras, Cuiying Chen – 29 October 2007 – We evaluated the use of blood serum N‐glycan fingerprinting as a tool for the diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosis induced by hepatitis B virus (HBV). A group of 450 HBV‐infected patients with liver fibrosis or cirrhosis with or without HCC were studied.

The role of serpinb9/serine protease inhibitor 6 in preventing granzyme B–dependent hepatotoxicity

Heather W. Stout‐Delgado, Yonas Getachew, Thomas E. Rogers, Bonnie C. Miller, Dwain L. Thiele – 29 October 2007 – Virally infected hepatocytes are resistant to cytotoxic lymphocyte killing by perforin‐dependent and granzyme‐dependent effector mechanisms. The present studies were designed to examine the role of serine protease inhibitor 6 (SPI‐6) in limiting granzyme B–dependent cytotoxic effector mechanisms in the liver.

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

Jordan J. Feld, Santosh Nanda, Ying Huang, Weiping Chen, Maggie Cam, Susan N. Pusek, Lisa M. Schweigler, Dickens Theodore, Steven L. Zacks, T. Jake Liang, Michael W. Fried – 29 October 2007 – The reasons for hepatitis C treatment failure remain unknown but may be related to different host responses to therapy. In this study, we compared hepatic gene expression in patients prior to and during peginterferon and ribavirin therapy.

Significance of nodular regenerative hyperplasia occurring de novo following liver transplantation

Harshad Devarbhavi, Susan Abraham, Patrick S. Kamath – 29 October 2007 – Nodular regenerative hyperplasia (NRH) of the liver usually occurs in patients with rheumatological and myelolymphoproliferative disorders; the occurrence post–liver transplantation (LT) has traditionally been ascribed to the use of azathioprine. We report the clinical, biochemical, and radiological features of 14 patients who developed NRH, unrelated to azathioprine in most cases, 3 months to 11 yr after orthotopic LT.

Subscribe to